{"title":"髓外骨髓瘤治疗的研究进展","authors":"Q. Cheng","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.05.012","DOIUrl":null,"url":null,"abstract":"Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy. \n \n \nKey words: \nMultiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"435-440"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress on treatment of extramedullary myeloma\",\"authors\":\"Q. Cheng\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.05.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy. \\n \\n \\nKey words: \\nMultiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"435-440\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.05.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Research progress on treatment of extramedullary myeloma
Extramedullary myeloma (EMM) refers to the presence of clonal plasma cells outside the bone marrow in a patient with multiple myeloma (MM). The development of novel agents and hematopoietic stem cell transplantation (HSCT) significantly extend the survival of patients with MM, but none of the current treatments can completely overcome the adverse prognosis of EMM, and the prognosis of EMM is still poor. It is important to understand the current status of EMM treatments and explore new therapies to improve the prognosis of EMM. This article summarizes the recent advances in the treatment of EMM, including chemotherapy, HSCT, cellular immunotherapy and molecular targeted therapy.
Key words:
Multiple myeloma; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Extramedullary myeloma; Chimeric antigen receptor-based immunotherapy
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
